We recently had the opportunity to interview Dr. Severien Van Keer, a post-doc researcher at the VAXINFECTIO research group, at the University of Antwerp. Her research primarily focuses on Human Papillomavirus (HPV) detection in first-void urine, and the potential of urine as a sample type for cervical cancer screening. Her research also includes Novosanis' Colli-Pee®, a first-void urine collection device.
You can listen to the full interview through our podcast:
Here are some of the key highlights from our discussion:
Cytology-based screening for cervical cancer through clinician-taken Pap smears has several limitations and women are often reluctant to participate in regular screening. Self-collection techniques have been recommended to improve screening uptake. HPV-based cervical cancer screening has shown to be more effective and efficient to increase participation in screening programs.
Women have shown a significantly higher preference to urine as a sample type for hrHPV testing, as the method is non-invasive and suitable for home-collection. Urine-based HPV testing has also shown similar sensitives to other sampling methods.
Tune in to hear Dr. Severien Van Keer’s view on some of the following questions:
- Can you tell us something about your research on urine and HPV detection?
- Why is HPV DNA detection replacing cytology as a primary cervical cancer screening test?
- What impact do you want to establish in the field of cervical cancer prevention?
- Can you explain the differences between urine and swabs for HPV detection?
- Are there pre-analytical requirements for the use of urine in HPV detection?
- What feedback did you receive from the physicians you cooperated with? And what feedback did you receive from the participating women?